Serving Size: 1 Capsule
Benfotiamine …...80 mg
Non-medicinal ingredients: microcrystalline cellulose, sodium stearyl fumarate. Capsule: hypromellose.
BenaGene™ is stabilized oxaloacetic acid, the world's first novel and natural Krebs cycle intermediate compound that is specifically formulated to be highly stable and bioavailable so that a one-a-day dosage is all that is required. BenaGene offers the potential of longevity and vitality and is exclusively available in Canada from AOR.
Caloric restriction is the only method proven to extend human lifespan and health span. BenaGene is a novel caloric restriction mimetic (CR mimetic), mimicking up to 98% of the changes in the genetic expression of over 350 genes in a similar fashion to caloric restriction. While human trials on BenaGene's effects on life extension have not been conducted, human clinical trials have confirmed both reduction in glucose levels and an improved uptake of glucose without negative side effects. BenaGene appears to down-regulate pathways that create and store fat. Mitochondrial and cellular DNA damage is also thought to exacerbate aging, and BenaGene both protects and repairs DNA.
Anyone who is interested in slowing down the aging process will want to consider taking BeneGene, as well as those who suffer from glucose imbalances. BenaGene is a perfect partner for resveratrol and other antioxidants, for even more powerful anti-aging effects.
ADULT DOSAGE: Take 1 capsule daily with food, or as directed by a qualified health care practitioner.
Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. “Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy.”
Nat Med. 2003 Mar; 9(3): 294-9.
Koltai MZ. “Prevention of cardiac autonomic neuropathy in dogs with Benfotiamine.”
In Gries FA, Federlin K. “
Benfotiamine in the Therapy of Polyneuropathy.”
New York: Georg Thieme Verlag, 1998; 45-9.
Lin J, Alt A, Liersch J, Bretzel RG, Brownlee MA, Hammes HP. “
Benfotiamine inhibits intracellular formation of advanced glycation endproducts in vivo.”
Diabetes. 2000 May; 49(Suppl1): A143 (P583).
Loew D. “
Pharmacokinetics of thiamine derivatives especially of Benfotiamine.”
Int J Clin Pharmacol Ther. 1996 Feb; 34(2): 47-50.
Stracke H, Lindemann A, Federlin K. “
A Benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy.”
Exp Clin Endocrinol Diabetes 1996; 104(4): 311-6.
Winkler G, Pal B, Nagybeganyi E, Ory I, Porochnavec M, Kempler P. “
Effectiveness of different Benfotiamine dosage regimens in the treatment of painful diabetic neuropathy.”
Arzneimittelforschung. 1999 Mar; 49(3): 220-4.
Disclaimer: This content is subject to change. The information is intended to inform and educate; it does not replace the medical evaluation, advice, diagnosis or treatment by a healthcare professional. www.nhpassist.com © 2014 NDAssist Inc. and/or its affiliates. All rights reserved.